Global Rectal Cancer Market

Rectal Cancer Comprehensive Study by Type (Stage 1, Stage 2, Stage 3, Stage 4), Application (Hospital, Clinic, Other), Treatment (Surgery, Radiation Therapy, Chemotherapy, Active Surveillance, Targeted Therapy, Immunotherapy), Test (Chest X-ray, Colonoscopy, CT scan, MRI, PET scan, Endorectal Ultrasound, Biopsy {RT-PCR test) Players and Region - Global Market Outlook to 2030

Rectal Cancer Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Rectal Cancer Market Scope
Rectal cancer is a disease diagnosed when a doctor tests to find the cause of bleeding or iron deficiency called anemia in the body. The surgical treatment is most widely used for rectal cancer and colonoscopy is said to be more accurate tests for detecting rectal cancer. In this, a doctor uses a thin and flexible lighted tube with a video at its tips called a colonoscope to easily view the inside of the colon and rectum. Some time rectal cancer can not show symptoms where a person comes to know about it when they go through the colonoscopy screening. The chances for recurrence of rectal cancer are higher after than in colorectal cancer as they have a slight difference in their treatment procedure.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledIsofol Medical Abs (Sweden), Pfizer Inc. (United States), Bristol Myers Squibb Company (United States), Merck & Co., Inc., (United States), Natera Inc. (United States), Genentech, Inc.(United States) and Sanofi S.A. (France)
CAGR%


Patients and their healthcare providers face a complex decision-making process when choosing the best treatment option. Factors like disease stage, overall health, treatment goals, and individual preferences play a crucial role. Consulting with experienced oncologists, surgeons, and radiation therapists is essential to understand the available options and make informed decisions.

Isofol Medical Abs (Sweden), Pfizer Inc. (United States), Bristol Myers Squibb Company (United States), Merck & Co., Inc., (United States), Natera Inc. (United States), Genentech, Inc.(United States) and Sanofi S.A. (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Advaxis Inc. (United States) and Seattle Genetics (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Rectal Cancer market by Type , by Application (Hospital, Clinic and Other) and Region with country level break-up.

On the basis of geography, the market of Rectal Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In December 2023, Roche partners with Flatiron Health to develop real-world evidence platform for rectal cancer treatments. This collaboration aims to leverage real-world data to monitor treatment effectiveness and identify potential areas for future research.
In November 2023, Roche introduces Foundation Medicine FoundationOne CDx for comprehensive genomic profiling of rectal cancer. This advanced test analyzes multiple genes and biomarkers, helping guide personalized treatment decisions based on the tumor's unique characteristics.


Influencing Trend:
Surgical Treatment is Most Common in Rectal Cancer and Improved Accuracy in Methods of Treating Rectal Cancer Because of Technological Advancements

Market Growth Drivers:
Growing Geriatric Population Across the World and Prevalence of Inflammatory Bowel Disease and Family History of Colorectal Cancer

Challenges:
Problems with Monitoring Treatment Response in Rectal Cancer

Restraints:
Recurrence of Rectal Cancer in Patients After Surgery in Some Cases

Opportunities:
Continuous Research and Development of Cancer Drugs and Increasing Spendings on Healthcare in the Developing Regions

Key Target Audience
Rectal Cancer Drugs and Devices Manufacturers, Rectal Cancer Treatment Providers, Hospital Associations, Research and Development Institutes, Investors and Venture Capital, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Stage 1
  • Stage 2
  • Stage 3
  • Stage 4
By Application
  • Hospital
  • Clinic
  • Other
By Treatment
  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Active Surveillance
  • Targeted Therapy
  • Immunotherapy

By Test
  • Chest X-ray
  • Colonoscopy
  • CT scan
  • MRI
  • PET scan
  • Endorectal Ultrasound
  • Biopsy {RT-PCR test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population Across the World
      • 3.2.2. Prevalence of Inflammatory Bowel Disease and Family History of Colorectal Cancer
    • 3.3. Market Challenges
      • 3.3.1. Problems with Monitoring Treatment Response in Rectal Cancer
    • 3.4. Market Trends
      • 3.4.1. Surgical Treatment is Most Common in Rectal Cancer
      • 3.4.2. Improved Accuracy in Methods of Treating Rectal Cancer Because of Technological Advancements
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rectal Cancer, by Type, Application, Treatment, Test and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Rectal Cancer (Value)
      • 5.2.1. Global Rectal Cancer by: Type (Value)
        • 5.2.1.1. Stage 1
        • 5.2.1.2. Stage 2
        • 5.2.1.3. Stage 3
        • 5.2.1.4. Stage 4
      • 5.2.2. Global Rectal Cancer by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Other
      • 5.2.3. Global Rectal Cancer by: Treatment (Value)
        • 5.2.3.1. Surgery
        • 5.2.3.2. Radiation Therapy
        • 5.2.3.3. Chemotherapy
        • 5.2.3.4. Active Surveillance
        • 5.2.3.5. Targeted Therapy
        • 5.2.3.6. Immunotherapy
      • 5.2.4. Global Rectal Cancer by: Test (Value)
        • 5.2.4.1. Chest X-ray
        • 5.2.4.2. Colonoscopy
        • 5.2.4.3. CT scan
        • 5.2.4.4. MRI
        • 5.2.4.5. PET scan
        • 5.2.4.6. Endorectal Ultrasound
        • 5.2.4.7. Biopsy {RT-PCR test
      • 5.2.5. Global Rectal Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Rectal Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Isofol Medical Abs (Sweden)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol Myers Squibb Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc., (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Natera Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genentech, Inc.(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A. (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Rectal Cancer Sale, by Type, Application, Treatment, Test and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Rectal Cancer (Value)
      • 7.2.1. Global Rectal Cancer by: Type (Value)
        • 7.2.1.1. Stage 1
        • 7.2.1.2. Stage 2
        • 7.2.1.3. Stage 3
        • 7.2.1.4. Stage 4
      • 7.2.2. Global Rectal Cancer by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Other
      • 7.2.3. Global Rectal Cancer by: Treatment (Value)
        • 7.2.3.1. Surgery
        • 7.2.3.2. Radiation Therapy
        • 7.2.3.3. Chemotherapy
        • 7.2.3.4. Active Surveillance
        • 7.2.3.5. Targeted Therapy
        • 7.2.3.6. Immunotherapy
      • 7.2.4. Global Rectal Cancer by: Test (Value)
        • 7.2.4.1. Chest X-ray
        • 7.2.4.2. Colonoscopy
        • 7.2.4.3. CT scan
        • 7.2.4.4. MRI
        • 7.2.4.5. PET scan
        • 7.2.4.6. Endorectal Ultrasound
        • 7.2.4.7. Biopsy {RT-PCR test
      • 7.2.5. Global Rectal Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rectal Cancer: by Type(USD Million)
  • Table 2. Rectal Cancer Stage 1 , by Region USD Million (2018-2023)
  • Table 3. Rectal Cancer Stage 2 , by Region USD Million (2018-2023)
  • Table 4. Rectal Cancer Stage 3 , by Region USD Million (2018-2023)
  • Table 5. Rectal Cancer Stage 4 , by Region USD Million (2018-2023)
  • Table 6. Rectal Cancer: by Application(USD Million)
  • Table 7. Rectal Cancer Hospital , by Region USD Million (2018-2023)
  • Table 8. Rectal Cancer Clinic , by Region USD Million (2018-2023)
  • Table 9. Rectal Cancer Other , by Region USD Million (2018-2023)
  • Table 10. Rectal Cancer: by Treatment(USD Million)
  • Table 11. Rectal Cancer Surgery , by Region USD Million (2018-2023)
  • Table 12. Rectal Cancer Radiation Therapy , by Region USD Million (2018-2023)
  • Table 13. Rectal Cancer Chemotherapy , by Region USD Million (2018-2023)
  • Table 14. Rectal Cancer Active Surveillance , by Region USD Million (2018-2023)
  • Table 15. Rectal Cancer Targeted Therapy , by Region USD Million (2018-2023)
  • Table 16. Rectal Cancer Immunotherapy , by Region USD Million (2018-2023)
  • Table 17. Rectal Cancer: by Test(USD Million)
  • Table 18. Rectal Cancer Chest X-ray , by Region USD Million (2018-2023)
  • Table 19. Rectal Cancer Colonoscopy , by Region USD Million (2018-2023)
  • Table 20. Rectal Cancer CT scan , by Region USD Million (2018-2023)
  • Table 21. Rectal Cancer MRI , by Region USD Million (2018-2023)
  • Table 22. Rectal Cancer PET scan , by Region USD Million (2018-2023)
  • Table 23. Rectal Cancer Endorectal Ultrasound , by Region USD Million (2018-2023)
  • Table 24. Rectal Cancer Biopsy {RT-PCR test , by Region USD Million (2018-2023)
  • Table 25. South America Rectal Cancer, by Country USD Million (2018-2023)
  • Table 26. South America Rectal Cancer, by Type USD Million (2018-2023)
  • Table 27. South America Rectal Cancer, by Application USD Million (2018-2023)
  • Table 28. South America Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 29. South America Rectal Cancer, by Test USD Million (2018-2023)
  • Table 30. Brazil Rectal Cancer, by Type USD Million (2018-2023)
  • Table 31. Brazil Rectal Cancer, by Application USD Million (2018-2023)
  • Table 32. Brazil Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 33. Brazil Rectal Cancer, by Test USD Million (2018-2023)
  • Table 34. Argentina Rectal Cancer, by Type USD Million (2018-2023)
  • Table 35. Argentina Rectal Cancer, by Application USD Million (2018-2023)
  • Table 36. Argentina Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 37. Argentina Rectal Cancer, by Test USD Million (2018-2023)
  • Table 38. Rest of South America Rectal Cancer, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Rectal Cancer, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 41. Rest of South America Rectal Cancer, by Test USD Million (2018-2023)
  • Table 42. Asia Pacific Rectal Cancer, by Country USD Million (2018-2023)
  • Table 43. Asia Pacific Rectal Cancer, by Type USD Million (2018-2023)
  • Table 44. Asia Pacific Rectal Cancer, by Application USD Million (2018-2023)
  • Table 45. Asia Pacific Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 46. Asia Pacific Rectal Cancer, by Test USD Million (2018-2023)
  • Table 47. China Rectal Cancer, by Type USD Million (2018-2023)
  • Table 48. China Rectal Cancer, by Application USD Million (2018-2023)
  • Table 49. China Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 50. China Rectal Cancer, by Test USD Million (2018-2023)
  • Table 51. Japan Rectal Cancer, by Type USD Million (2018-2023)
  • Table 52. Japan Rectal Cancer, by Application USD Million (2018-2023)
  • Table 53. Japan Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 54. Japan Rectal Cancer, by Test USD Million (2018-2023)
  • Table 55. India Rectal Cancer, by Type USD Million (2018-2023)
  • Table 56. India Rectal Cancer, by Application USD Million (2018-2023)
  • Table 57. India Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 58. India Rectal Cancer, by Test USD Million (2018-2023)
  • Table 59. South Korea Rectal Cancer, by Type USD Million (2018-2023)
  • Table 60. South Korea Rectal Cancer, by Application USD Million (2018-2023)
  • Table 61. South Korea Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 62. South Korea Rectal Cancer, by Test USD Million (2018-2023)
  • Table 63. Taiwan Rectal Cancer, by Type USD Million (2018-2023)
  • Table 64. Taiwan Rectal Cancer, by Application USD Million (2018-2023)
  • Table 65. Taiwan Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 66. Taiwan Rectal Cancer, by Test USD Million (2018-2023)
  • Table 67. Australia Rectal Cancer, by Type USD Million (2018-2023)
  • Table 68. Australia Rectal Cancer, by Application USD Million (2018-2023)
  • Table 69. Australia Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 70. Australia Rectal Cancer, by Test USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Rectal Cancer, by Type USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Rectal Cancer, by Application USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Rectal Cancer, by Test USD Million (2018-2023)
  • Table 75. Europe Rectal Cancer, by Country USD Million (2018-2023)
  • Table 76. Europe Rectal Cancer, by Type USD Million (2018-2023)
  • Table 77. Europe Rectal Cancer, by Application USD Million (2018-2023)
  • Table 78. Europe Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 79. Europe Rectal Cancer, by Test USD Million (2018-2023)
  • Table 80. Germany Rectal Cancer, by Type USD Million (2018-2023)
  • Table 81. Germany Rectal Cancer, by Application USD Million (2018-2023)
  • Table 82. Germany Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 83. Germany Rectal Cancer, by Test USD Million (2018-2023)
  • Table 84. France Rectal Cancer, by Type USD Million (2018-2023)
  • Table 85. France Rectal Cancer, by Application USD Million (2018-2023)
  • Table 86. France Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 87. France Rectal Cancer, by Test USD Million (2018-2023)
  • Table 88. Italy Rectal Cancer, by Type USD Million (2018-2023)
  • Table 89. Italy Rectal Cancer, by Application USD Million (2018-2023)
  • Table 90. Italy Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 91. Italy Rectal Cancer, by Test USD Million (2018-2023)
  • Table 92. United Kingdom Rectal Cancer, by Type USD Million (2018-2023)
  • Table 93. United Kingdom Rectal Cancer, by Application USD Million (2018-2023)
  • Table 94. United Kingdom Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 95. United Kingdom Rectal Cancer, by Test USD Million (2018-2023)
  • Table 96. Netherlands Rectal Cancer, by Type USD Million (2018-2023)
  • Table 97. Netherlands Rectal Cancer, by Application USD Million (2018-2023)
  • Table 98. Netherlands Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 99. Netherlands Rectal Cancer, by Test USD Million (2018-2023)
  • Table 100. Rest of Europe Rectal Cancer, by Type USD Million (2018-2023)
  • Table 101. Rest of Europe Rectal Cancer, by Application USD Million (2018-2023)
  • Table 102. Rest of Europe Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 103. Rest of Europe Rectal Cancer, by Test USD Million (2018-2023)
  • Table 104. MEA Rectal Cancer, by Country USD Million (2018-2023)
  • Table 105. MEA Rectal Cancer, by Type USD Million (2018-2023)
  • Table 106. MEA Rectal Cancer, by Application USD Million (2018-2023)
  • Table 107. MEA Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 108. MEA Rectal Cancer, by Test USD Million (2018-2023)
  • Table 109. Middle East Rectal Cancer, by Type USD Million (2018-2023)
  • Table 110. Middle East Rectal Cancer, by Application USD Million (2018-2023)
  • Table 111. Middle East Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 112. Middle East Rectal Cancer, by Test USD Million (2018-2023)
  • Table 113. Africa Rectal Cancer, by Type USD Million (2018-2023)
  • Table 114. Africa Rectal Cancer, by Application USD Million (2018-2023)
  • Table 115. Africa Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 116. Africa Rectal Cancer, by Test USD Million (2018-2023)
  • Table 117. North America Rectal Cancer, by Country USD Million (2018-2023)
  • Table 118. North America Rectal Cancer, by Type USD Million (2018-2023)
  • Table 119. North America Rectal Cancer, by Application USD Million (2018-2023)
  • Table 120. North America Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 121. North America Rectal Cancer, by Test USD Million (2018-2023)
  • Table 122. United States Rectal Cancer, by Type USD Million (2018-2023)
  • Table 123. United States Rectal Cancer, by Application USD Million (2018-2023)
  • Table 124. United States Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 125. United States Rectal Cancer, by Test USD Million (2018-2023)
  • Table 126. Canada Rectal Cancer, by Type USD Million (2018-2023)
  • Table 127. Canada Rectal Cancer, by Application USD Million (2018-2023)
  • Table 128. Canada Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 129. Canada Rectal Cancer, by Test USD Million (2018-2023)
  • Table 130. Mexico Rectal Cancer, by Type USD Million (2018-2023)
  • Table 131. Mexico Rectal Cancer, by Application USD Million (2018-2023)
  • Table 132. Mexico Rectal Cancer, by Treatment USD Million (2018-2023)
  • Table 133. Mexico Rectal Cancer, by Test USD Million (2018-2023)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Rectal Cancer: by Type(USD Million)
  • Table 142. Rectal Cancer Stage 1 , by Region USD Million (2025-2030)
  • Table 143. Rectal Cancer Stage 2 , by Region USD Million (2025-2030)
  • Table 144. Rectal Cancer Stage 3 , by Region USD Million (2025-2030)
  • Table 145. Rectal Cancer Stage 4 , by Region USD Million (2025-2030)
  • Table 146. Rectal Cancer: by Application(USD Million)
  • Table 147. Rectal Cancer Hospital , by Region USD Million (2025-2030)
  • Table 148. Rectal Cancer Clinic , by Region USD Million (2025-2030)
  • Table 149. Rectal Cancer Other , by Region USD Million (2025-2030)
  • Table 150. Rectal Cancer: by Treatment(USD Million)
  • Table 151. Rectal Cancer Surgery , by Region USD Million (2025-2030)
  • Table 152. Rectal Cancer Radiation Therapy , by Region USD Million (2025-2030)
  • Table 153. Rectal Cancer Chemotherapy , by Region USD Million (2025-2030)
  • Table 154. Rectal Cancer Active Surveillance , by Region USD Million (2025-2030)
  • Table 155. Rectal Cancer Targeted Therapy , by Region USD Million (2025-2030)
  • Table 156. Rectal Cancer Immunotherapy , by Region USD Million (2025-2030)
  • Table 157. Rectal Cancer: by Test(USD Million)
  • Table 158. Rectal Cancer Chest X-ray , by Region USD Million (2025-2030)
  • Table 159. Rectal Cancer Colonoscopy , by Region USD Million (2025-2030)
  • Table 160. Rectal Cancer CT scan , by Region USD Million (2025-2030)
  • Table 161. Rectal Cancer MRI , by Region USD Million (2025-2030)
  • Table 162. Rectal Cancer PET scan , by Region USD Million (2025-2030)
  • Table 163. Rectal Cancer Endorectal Ultrasound , by Region USD Million (2025-2030)
  • Table 164. Rectal Cancer Biopsy {RT-PCR test , by Region USD Million (2025-2030)
  • Table 165. South America Rectal Cancer, by Country USD Million (2025-2030)
  • Table 166. South America Rectal Cancer, by Type USD Million (2025-2030)
  • Table 167. South America Rectal Cancer, by Application USD Million (2025-2030)
  • Table 168. South America Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 169. South America Rectal Cancer, by Test USD Million (2025-2030)
  • Table 170. Brazil Rectal Cancer, by Type USD Million (2025-2030)
  • Table 171. Brazil Rectal Cancer, by Application USD Million (2025-2030)
  • Table 172. Brazil Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 173. Brazil Rectal Cancer, by Test USD Million (2025-2030)
  • Table 174. Argentina Rectal Cancer, by Type USD Million (2025-2030)
  • Table 175. Argentina Rectal Cancer, by Application USD Million (2025-2030)
  • Table 176. Argentina Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 177. Argentina Rectal Cancer, by Test USD Million (2025-2030)
  • Table 178. Rest of South America Rectal Cancer, by Type USD Million (2025-2030)
  • Table 179. Rest of South America Rectal Cancer, by Application USD Million (2025-2030)
  • Table 180. Rest of South America Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 181. Rest of South America Rectal Cancer, by Test USD Million (2025-2030)
  • Table 182. Asia Pacific Rectal Cancer, by Country USD Million (2025-2030)
  • Table 183. Asia Pacific Rectal Cancer, by Type USD Million (2025-2030)
  • Table 184. Asia Pacific Rectal Cancer, by Application USD Million (2025-2030)
  • Table 185. Asia Pacific Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 186. Asia Pacific Rectal Cancer, by Test USD Million (2025-2030)
  • Table 187. China Rectal Cancer, by Type USD Million (2025-2030)
  • Table 188. China Rectal Cancer, by Application USD Million (2025-2030)
  • Table 189. China Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 190. China Rectal Cancer, by Test USD Million (2025-2030)
  • Table 191. Japan Rectal Cancer, by Type USD Million (2025-2030)
  • Table 192. Japan Rectal Cancer, by Application USD Million (2025-2030)
  • Table 193. Japan Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 194. Japan Rectal Cancer, by Test USD Million (2025-2030)
  • Table 195. India Rectal Cancer, by Type USD Million (2025-2030)
  • Table 196. India Rectal Cancer, by Application USD Million (2025-2030)
  • Table 197. India Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 198. India Rectal Cancer, by Test USD Million (2025-2030)
  • Table 199. South Korea Rectal Cancer, by Type USD Million (2025-2030)
  • Table 200. South Korea Rectal Cancer, by Application USD Million (2025-2030)
  • Table 201. South Korea Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 202. South Korea Rectal Cancer, by Test USD Million (2025-2030)
  • Table 203. Taiwan Rectal Cancer, by Type USD Million (2025-2030)
  • Table 204. Taiwan Rectal Cancer, by Application USD Million (2025-2030)
  • Table 205. Taiwan Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 206. Taiwan Rectal Cancer, by Test USD Million (2025-2030)
  • Table 207. Australia Rectal Cancer, by Type USD Million (2025-2030)
  • Table 208. Australia Rectal Cancer, by Application USD Million (2025-2030)
  • Table 209. Australia Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 210. Australia Rectal Cancer, by Test USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Rectal Cancer, by Type USD Million (2025-2030)
  • Table 212. Rest of Asia-Pacific Rectal Cancer, by Application USD Million (2025-2030)
  • Table 213. Rest of Asia-Pacific Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 214. Rest of Asia-Pacific Rectal Cancer, by Test USD Million (2025-2030)
  • Table 215. Europe Rectal Cancer, by Country USD Million (2025-2030)
  • Table 216. Europe Rectal Cancer, by Type USD Million (2025-2030)
  • Table 217. Europe Rectal Cancer, by Application USD Million (2025-2030)
  • Table 218. Europe Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 219. Europe Rectal Cancer, by Test USD Million (2025-2030)
  • Table 220. Germany Rectal Cancer, by Type USD Million (2025-2030)
  • Table 221. Germany Rectal Cancer, by Application USD Million (2025-2030)
  • Table 222. Germany Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 223. Germany Rectal Cancer, by Test USD Million (2025-2030)
  • Table 224. France Rectal Cancer, by Type USD Million (2025-2030)
  • Table 225. France Rectal Cancer, by Application USD Million (2025-2030)
  • Table 226. France Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 227. France Rectal Cancer, by Test USD Million (2025-2030)
  • Table 228. Italy Rectal Cancer, by Type USD Million (2025-2030)
  • Table 229. Italy Rectal Cancer, by Application USD Million (2025-2030)
  • Table 230. Italy Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 231. Italy Rectal Cancer, by Test USD Million (2025-2030)
  • Table 232. United Kingdom Rectal Cancer, by Type USD Million (2025-2030)
  • Table 233. United Kingdom Rectal Cancer, by Application USD Million (2025-2030)
  • Table 234. United Kingdom Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 235. United Kingdom Rectal Cancer, by Test USD Million (2025-2030)
  • Table 236. Netherlands Rectal Cancer, by Type USD Million (2025-2030)
  • Table 237. Netherlands Rectal Cancer, by Application USD Million (2025-2030)
  • Table 238. Netherlands Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 239. Netherlands Rectal Cancer, by Test USD Million (2025-2030)
  • Table 240. Rest of Europe Rectal Cancer, by Type USD Million (2025-2030)
  • Table 241. Rest of Europe Rectal Cancer, by Application USD Million (2025-2030)
  • Table 242. Rest of Europe Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 243. Rest of Europe Rectal Cancer, by Test USD Million (2025-2030)
  • Table 244. MEA Rectal Cancer, by Country USD Million (2025-2030)
  • Table 245. MEA Rectal Cancer, by Type USD Million (2025-2030)
  • Table 246. MEA Rectal Cancer, by Application USD Million (2025-2030)
  • Table 247. MEA Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 248. MEA Rectal Cancer, by Test USD Million (2025-2030)
  • Table 249. Middle East Rectal Cancer, by Type USD Million (2025-2030)
  • Table 250. Middle East Rectal Cancer, by Application USD Million (2025-2030)
  • Table 251. Middle East Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 252. Middle East Rectal Cancer, by Test USD Million (2025-2030)
  • Table 253. Africa Rectal Cancer, by Type USD Million (2025-2030)
  • Table 254. Africa Rectal Cancer, by Application USD Million (2025-2030)
  • Table 255. Africa Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 256. Africa Rectal Cancer, by Test USD Million (2025-2030)
  • Table 257. North America Rectal Cancer, by Country USD Million (2025-2030)
  • Table 258. North America Rectal Cancer, by Type USD Million (2025-2030)
  • Table 259. North America Rectal Cancer, by Application USD Million (2025-2030)
  • Table 260. North America Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 261. North America Rectal Cancer, by Test USD Million (2025-2030)
  • Table 262. United States Rectal Cancer, by Type USD Million (2025-2030)
  • Table 263. United States Rectal Cancer, by Application USD Million (2025-2030)
  • Table 264. United States Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 265. United States Rectal Cancer, by Test USD Million (2025-2030)
  • Table 266. Canada Rectal Cancer, by Type USD Million (2025-2030)
  • Table 267. Canada Rectal Cancer, by Application USD Million (2025-2030)
  • Table 268. Canada Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 269. Canada Rectal Cancer, by Test USD Million (2025-2030)
  • Table 270. Mexico Rectal Cancer, by Type USD Million (2025-2030)
  • Table 271. Mexico Rectal Cancer, by Application USD Million (2025-2030)
  • Table 272. Mexico Rectal Cancer, by Treatment USD Million (2025-2030)
  • Table 273. Mexico Rectal Cancer, by Test USD Million (2025-2030)
  • Table 274. Research Programs/Design for This Report
  • Table 275. Key Data Information from Secondary Sources
  • Table 276. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rectal Cancer: by Type USD Million (2018-2023)
  • Figure 5. Global Rectal Cancer: by Application USD Million (2018-2023)
  • Figure 6. Global Rectal Cancer: by Treatment USD Million (2018-2023)
  • Figure 7. Global Rectal Cancer: by Test USD Million (2018-2023)
  • Figure 8. South America Rectal Cancer Share (%), by Country
  • Figure 9. Asia Pacific Rectal Cancer Share (%), by Country
  • Figure 10. Europe Rectal Cancer Share (%), by Country
  • Figure 11. MEA Rectal Cancer Share (%), by Country
  • Figure 12. North America Rectal Cancer Share (%), by Country
  • Figure 13. Global Rectal Cancer share by Players 2023 (%)
  • Figure 14. Global Rectal Cancer share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Isofol Medical Abs (Sweden) Revenue, Net Income and Gross profit
  • Figure 17. Isofol Medical Abs (Sweden) Revenue: by Geography 2023
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Bristol Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bristol Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 22. Merck & Co., Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc., (United States) Revenue: by Geography 2023
  • Figure 24. Natera Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Natera Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Genentech, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 27. Genentech, Inc.(United States) Revenue: by Geography 2023
  • Figure 28. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 30. Global Rectal Cancer: by Type USD Million (2025-2030)
  • Figure 31. Global Rectal Cancer: by Application USD Million (2025-2030)
  • Figure 32. Global Rectal Cancer: by Treatment USD Million (2025-2030)
  • Figure 33. Global Rectal Cancer: by Test USD Million (2025-2030)
  • Figure 34. South America Rectal Cancer Share (%), by Country
  • Figure 35. Asia Pacific Rectal Cancer Share (%), by Country
  • Figure 36. Europe Rectal Cancer Share (%), by Country
  • Figure 37. MEA Rectal Cancer Share (%), by Country
  • Figure 38. North America Rectal Cancer Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Isofol Medical Abs (Sweden)
  • Pfizer Inc. (United States)
  • Bristol Myers Squibb Company (United States)
  • Merck & Co., Inc., (United States)
  • Natera Inc. (United States)
  • Genentech, Inc.(United States)
  • Sanofi S.A. (France)
Additional players considered in the study are as follows:
Advaxis Inc. (United States) , Seattle Genetics (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 205 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Rectal Cancer Market Quantitative research analysis
Global Rectal Cancer Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Rectal Cancer Market are by type [Stage 1, Stage 2, Stage 3 and Stage 4], by end use application [Hospital, Clinic and Other].
The Rectal Cancer Market is gaining popularity and expected to see strong valuation by 2030.
  • Growing Geriatric Population Across the World
  • Prevalence of Inflammatory Bowel Disease and Family History of Colorectal Cancer

Know More About Global Rectal Cancer Market Report?

Have a Query? Click Here

Other Related Reports

Myocardial Infarction Treatment Comprehensive Study by Type (Supportive Care {Defibrillation, Oxygen}, Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor}, Therapy ...
$ 3750
Neurorehabilitation Comprehensive Study by Type (Traumatic Brain Injury (TBI), Acquired Brain Injury (ABI)), Application (General Hospital, Rehabilitation Specialist Hospital, Community Rehabilitatio...
$ 3650
Infusion Therapy Comprehensive Study by Type (Intravenous Set, Needleless Catheter, Infusion Pump), Application (Chemotherapy, Diabetes, Hydration Therapy, Inotropic Therapy, Pain Management, HIV, Po...
$ 3750
Hantavirus Comprehensive Study by Type (Sin Nombre, Black Creek Hantavirus, Seoul Virus, New York Hantavirus), Application (Hospitals, Clinics, Intensive Care Unit), Treatment (Mechanical Ventilation...
$ 3650
Edema Clinical Comprehensive Study by Type (Systematic Edema Clinical {Cardiac Disease, Hepatic Disease, Renal Disease, Others}, Local Edema Clinical {Cellulitis, Chronic Venous Insufficiency, Others...
$ 3750
Stereotactic Radiosurgery Comprehensive Study by Application (Brain Tumors, Arteriovenous Malformations (AVMs), Trigeminal Neuralgia, Tremor, Others), End-User (Hospitals, Clinics, Ambulatory Surgery...
$ 3650